Inhibitors of p56lck: assessing their potential as tools for manipulating T-lymphocyte activation

Bibliography

• CHAN AC, DESAI DM, WEISS A: The role of protein- tyrosine kinases and protein-tyrosine phosphatases in T-cell antigen receptor signal-transduction. Ann. Rev. Immunol. (1994) 12:555–592.
   PubMed Web of Science ®Google Scholar
• WEISS A, LITTMAN D: Signal transduction by lympho-cyte antigen receptors. Cell (1994) 76:263–266.
   PubMed Web of Science ®Google Scholar
• STRAUS DB, WEISS A: Genetic evidence for the involve-ment of the I_Ac tyrosine kinase in signal transduction through the T-cell antigen receptor. Cell (1992) 70:585–593.
   PubMed Web of Science ®Google Scholar
• ••Indicates that Lck is required for normal signal transductionthrough the TCR.
   Google Scholar
• SHAW AS, AMREIN KE, HAMMOND C, STERN DF, SEFTON BM, ROSE JK: The I_Ac tyrosine protein-kinase interacts with the cytoplasmic tail of the CD4 glycoprotein through its unique amino-terminal domain. Cell (1989) 59:627–635.
   PubMed Web of Science ®Google Scholar
• RUDD CE, TREVILLYAN JM, DASGUPTA JD, WONG LL, SCHLOSSMAN SF: The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. Proc. Natl. Acad. Sci USA (1988) 85:5190–5194.
   PubMed Web of Science ®Google Scholar
• BARBER EK, DASGUPTA JD, SCHLOSSMAN SF, TREVIL-LYAN JM, RUDD CE: The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56") that phosphorylates the CD3 complex. Proc. Natl. Acad. Sci USA (1989) 86:3277–3281.
   PubMed Web of Science ®Google Scholar
• ZHOU YJ, MAGNUSON KS, CHENG TP et al.: Hierarchy of protein tyrosine kinases in interleukin-2 (112) signal-ling: activation of Syk depends on Jak3; however, neither Syk nor I_Ac is required for IL-2-mediated STAT activation. Mol. Cell. Biol. (2000) 20:4371–4380.
   PubMed Web of Science ®Google Scholar
• WARD SG: CD28: a signalling perspective. Biochem.(1996) 318:361–377.
   Google Scholar
• VAN OERS NSC, LOWINKROPF B, FINLAY D, CONNOLLY K, WEISS A: c43 T cell development is abolished in mice lacking both I_Ac and Fyn protein tyrosine kinases. Immunity (1996) 5:429–436.
   PubMed Web of Science ®Google Scholar
• ••Lck is the major Src family member required for thymopoie-sis, since there is a severe deficit of CD4+/CD8+ thymocytes and mature T-cells in its absence.
   Google Scholar
• STEFANOVA I, SAVILLE MW, PETERS C et al.: HIV infection-induced post-translational modification of T cell signalling molecules associated with disease progression. J Clin. Invest. (1996) 98:1290–1297.
   PubMed Web of Science ®Google Scholar
• TREVILLYAN JM, CHIOU XG, BALLARON SJ et al.: Inhibi-tion of p 56" tyrosine kinase by isothiazolones. Arch. Biochem. Biophys. (1999) 364:19–29.
   PubMed Web of Science ®Google Scholar
• •Novel isothiazalone identified as a potent mechanism-based inhibitor of p56".
   Google Scholar
• KIRSCH G, KONIG GM, WRIGHT AD, KAMINSKY R: Anew bioactive sesterterpene and antiplasmodial alkaloids from the Marine Sponge Hyrtios cf. erecta. J. Nat. Prod. (2000) 63:825–829.
   PubMed Web of Science ®Google Scholar
• OSTERHAGE C, KAMINSKY R, KONIG GM, WRIGHT AD: Ascosalipyrrolidinone A, an antimicrobial alkaloid, from the obligate marine fungus Ascochyta salkor-niae. J. Org. Chem (2000) 65:6412–6417.
   PubMed Web of Science ®Google Scholar
• PADMANABHA R, SHU YZ, COOK LS et al.: 1-methoxy-agroclavine from Penicillium sp. WC75209, a novel inhibitor of the I_Ac tyrosine kinase. Bioorg. Med. Chem. Lett. (1998) 8:569–574
   Google Scholar
• •High-throughput screening identified a low molecular mass inhibitor of p561ck from a fungal culture.
   Google Scholar
• BULLINGTON JL, CAMERON JC, DAVIS JE et al.: The development of novel and selective p56" tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. (1998) 8:2489–2494.
   PubMed Web of Science ®Google Scholar
• MYERS MR, SETZER NN, SPADA AP et al: The preparationand SAR of 4-(anilino), 4-(phenoxy) and 4-(thiophe-noxy)-quinazolines: inhibitors of p56" and EGF-R tyrosine kinase activity. Bioorg. Med. Chem. Lett. (1997) 7:417–420.
   Web of Science ®Google Scholar
• KRAKER AJ, HARTL BG, AMAR AM, BRAVIAN MR, SHOWALTER HDH, MOORE CW: Biochemical and cellular effects of c-Src kin ase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol. (2000) 60:885–898.
   PubMed Web of Science ®Google Scholar
• ••Highly potent and somewhat selective inhibitors aredescribed.
   Google Scholar
• HANKE JH, GARDNER JP, DOW RL et al.: Discovery of a novel, potent and Src family-selective tyrosine kinase inhibitor: study of I_Ac- and FynT-dependent T cell activation. J Biol. Chem. (1996) 271:695–701.
   PubMed Web of Science ®Google Scholar
• ZHU XT, KIM JL, NEWCOMB JR et al: Structural analysis of the lymphocyte-specific kinase I_Ac in complex with non-selective and Src family selective kinase Struct. Fold. Des. (1999) 7:651–661.
   Google Scholar
• ••PP2 is found to access a deep, hydrophobic pocket near theATP-binding cleft of the enzyme. The amino acid composi-tion of this pocket is unique to Src family kinases and provides the basis for selective inhibition.
   Google Scholar
• IMSA U, MITCHISON A, ALLEN R: Inhibitors of Src-family tyrosine kinases favour Th2 differentiation. Cytokine (1999) 11:208–215.
   PubMed Web of Science ®Google Scholar
• ARNOLD LD, CALDERWOOD DJ, DIXON RW et al.: Pyrrolo [2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inibitors of I_Ac Bioorg. Med. Chem. Lett. (2000) 10:2167–2170.
   PubMed Web of Science ®Google Scholar
• ••Phenoxyphenyl group provides access to hydrophobicpocket adjacent to the ATP binding site, affording highly potent and selective inhibitors.
   Google Scholar
• BURCHAT AF, CALDERWOOD DJ, HIRST GC et al.: Pyrrolo [2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of I_Ac (II). Bioorg. Med. Chem. Lett. (2000) 10:2171–2174.
   PubMed Web of Science ®Google Scholar
• LLINAS-BRUNET M, BEAULIEU PL, CAMERON DR et al.: Phosphotyrosine containing dipeptides as high affinity ligands for the p56" 51–12 domain. J Med. Chem. (1999) 42:722-729.© Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(2)
   Google Scholar
• BEAULIEU PL, CAMERON DR, FERLAND J-M et al.: ligands for the tyrosine kinase p56" SH2 domain: discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements. J. Med. Chem. (1999) 42:1757–1766.
   PubMed Web of Science ®Google Scholar
• LEE TR, LAWRENCE DS: SH2-directed ligands of the IAc tyrosine kinase. J Med. Chem. (2000) 43:1173–1179.
   PubMed Web of Science ®Google Scholar
• SHUKER SB, HADJUK PJ, MEADOWS RP, FESIK SW: Discovering high-affinity ligands for proteins: SAR by Is111111. Science (1996) 274:1531–1534.
   PubMed Web of Science ®Google Scholar
• HAJDUK PJ, MEADOWS R.P, FESIK SW: Drug design: discovering high-affinity ligands for proteins. Science (1997) 278:497.
   PubMed Web of Science ®Google Scholar
• HAJDUK PJ, ZHOU MM, FESIK SW: NNIR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain. Bioorg. Med. Chem. Lett. (1999) 9:2403–2406.
   PubMed Web of Science ®Google Scholar
• BISHOP AC, UBERSAX JA, PETSCH DT et al: A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature (2000) 407:395–401.
   PubMed Web of Science ®Google Scholar
• ••Novel approach of considerable importance and broadsignificance.
   Google Scholar